Second-Look Ultrasound Post Contrast-Enhanced Mammography for Additional Lesions Characterization
Launched by GRAZIELLA DI GREZIA · Feb 20, 2025
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The goal is to assess the diagnostic accuracy and clinical value of combining CEM with targeted ultrasound to improve lesion characterization and guide biopsy decisions.
Gender
FEMALE
Eligibility criteria
- INCLUSION CRITERIA:
- • Patients undergoing contrast-enhanced mammography for diagnostic or surveillance purposes.
- • Identification of additional lesions on CEM requiring further evaluation.
- • Ability to provide informed consent.
- EXCLUSION CRITERIA:
- • Known breast cancer diagnosis without suspicion of additional lesions.
- • Contraindications to ultrasound or contrast agents.
- • Patients with incomplete imaging data.
About Graziella Di Grezia
Graziella Di Grezia is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on integrity and ethical standards, the organization collaborates with healthcare professionals and institutions to conduct rigorous trials across various therapeutic areas. Graziella Di Grezia prioritizes patient safety and data integrity, leveraging cutting-edge methodologies and comprehensive monitoring to ensure the highest quality of clinical research. Their mission is to contribute to the development of effective treatments and enhance the understanding of medical conditions, ultimately benefiting patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Naples, , Italy
Patients applied
Trial Officials
Graziella Di Grezia, Medicine
Principal Investigator
Link Campus University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported